The Joint Meeting of the American Academy of Sleep Medicine and Sleep Research Society (SLEEP)

The associate professor of neurology at the Icahn School of Medicine at Mount Sinai explained how his team validated an iRBD actigraphy classifier across new devices and datasets to enhance early, scalable screening for neurodegenerative disease. [WATCH TIME: 5 minutes]

The sleep and stroke neurologist at Barrow Neurological Institute provided insights on the potential of sleep-boosting strategies—including pharmacologic options—to enhance glymphatic clearance and improve stroke recovery outcomes. [WATCH TIME: 4 minutes]

The postdoctoral researcher at the Woolcock Institute of Medical Research highlighted EEG-based evidence supporting ALKS 2680's wake-promoting effects in patients with narcolepsy and idiopathic hypersomnia. [WATCH TIME: 3 minutes]

Omonigho Michael Bubu, MD, PhD, an associate professor of psychiatry, neurology, & population health at NYU Langone, discussed how OSA contributes to Alzheimer disease risk through race- and sex-specific mechanisms and neurodegenerative biomarkers.

Richard Bogan, MD, FCCP, FAASM, an associate clinical professor at the University of South Carolina School of Medicine, discussed a bevy of presentations from the 2025 SLEEP Annual Meeting highlighting the effects of once-nightly sodium oxybate.

Anita Shelgikar, MD, a clinical professor at the University of Michigan and president of the American Academy of Sleep Medicine, provided post-conference perspectives on the 2025 SLEEP meeting, giving clinicians insights on the latest in research and treatment updates.

Centessa Pharmaceuticals initiates Phase 1 study for ORX142, a novel orexin receptor agonist targeting neurological disorders, promising new treatment avenues.

The neuropathologist at Mayo Clinic Florida discussed why EEG-based sleep biomarkers may help detect Alzheimer disease earlier and how they could enhance clinical trial design. [WATCH TIME: 3 minutes]

The chief executive officer of Restful Sleep MD emphasized the importance of tailoring pediatric sleep interventions to each family’s unique structure, values, and challenges. [WATCH TIME: 5 minutes]

The director of sleep health at Flinders University discussed the latest clinical advances in pharmacotherapy, precision treatment targets, and combination strategies for obstructive sleep apnea.

Deepa Burman, MD, FAASM, co-director of the Pediatric Sleep Evaluation Center at UPMC Children’s Hospital of Pittsburgh, discussed the potential contributors to pediatric insomnia and the role of a thorough assessment for effective management.

Neurology News Network. for the week ending June 14, 2025. [WATCH TIME: 4 minutes]

Funke Afolabi-Brown, MD, FAASM, chief executive officer of Restful Sleep MD, discussed the potential role of family dynamics and individualized planning in the effective management of pediatric sleep disorders.

A new phase 2 study explores samelisant's potential to treat cataplexy in narcolepsy type 1, promising improved patient outcomes and safety.

New 5-year findings from the National RLS Opioid Registry presented at SLEEP 2025 highlight the long-term stability and dose trends of low-dose opioid therapy in patients with restless legs syndrome.

Switching to once-nightly sodium oxybate significantly improves sleep-related eating disorder in narcolepsy patients, enhancing overall treatment outcomes.

An interim analysis of an ongoing study suggested that the tonic motor activation demonstrated comparable short-term outcomes for both painful and painless forms of restless legs syndrome.

The sleep and stroke neurologist at Barrow Neurological Institute detailed how improving glymphatic function may prevent strokes and enhance recovery from both hemorrhagic and ischemic events. [WATCH TIME: 5 minutes]

Findings from the Jazz DUET study presented at SLEEP 2025 showed that low-sodium oxybate reduced daytime sleepiness and improved sleep parameters in patients with narcolepsy types 1 and 2.

The neuropathologist at Mayo Clinic Florida discussed her presentation from SLEEP 2025, outlining how early tau accumulation in wake-promoting brain regions contributes to sleep disturbances before Alzheimer disease symptoms arise. [WATCH TIME: 3 minutes]

The neuroscientist and physician at Mount Sinai explored the role of sleep-dependent brain clearance in Alzheimer disease and how emerging research is challenging longstanding assumptions.

Data from a pair of phase 3 trials suggest that tirzepatide treatment may improve patient-reported measures of sleepiness in individuals with obstructive sleep apnea and obesity.

The professor of psychology at the University of Tulsa provided insight on how her team adapted CBT for children with nightmares using a learning-theory approach that targets the fear-avoidance cycle. [WATCH TIME: 5 minutes]

New phase 2 trial data presented at SLEEP 2025 suggest TAK-861 significantly decreased microsleep frequency and delayed onset of first microsleep in individuals with narcolepsy type 1.

New analysis reveals insights on hypnagogic and hypnopompic hallucinations in narcolepsy patients treated with once-nightly sodium oxybate.

The director of sleep health at Flinders University explained how new mechanistic insights are enabling targeted pharmacotherapy and trait-based treatment for obstructive sleep apnea. [WATCH TIME: 3 minutes]

A newly presented actigraphy-based algorithm demonstrated high accuracy in detecting daytime naps, offering insights into napping behavior changes in patients with narcolepsy type 1.

A recent analysis reveals the safety profile of once-nightly sodium oxybate for narcolepsy, highlighting low discontinuation rates and common adverse events.

A new study presented at SLEEP 2025 reported that more than one-quarter of pregnant women experienced restless legs syndrome, with prior history of the condition emerging as a significant risk factor.

New research reveals solriamfetol significantly enhances neuropsychological outcomes in patients with obstructive sleep apnea and excessive daytime sleepiness.